Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 11,422,978 | $178,655,376 | +1% | 6.63% |
| 2. | Rubric Capital Management David Rosen | 10,966,672 | $171,518,750 | 3.07% | |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 6,706,475 | $104,889,269 | -10% | 0.64% |
| 4. | D E Shaw D. E. Shaw | 1,989,508 | $31,115,905 | -21% | 0.03% |
| 5. | Cormorant Asset Management Bihua Chen | 1,350,000 | $21,114,000 | -27% | 1.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.08 | 2,646 | $34,610.47 | 27,448 | 2025-06-13 | Filing | |
| $13.41 | 378 | $5,069.28 | 24,802 | 2025-06-05 | Filing | |
| $13.32 | 1,890 | $25,177.45 | 24,424 | 2025-06-04 | Filing | |
| $13.65 | 2,520 | $34,398.00 | 22,534 | 2025-05-22 | Filing | |
| $13.66 | 2,520 | $34,423.20 | 20,014 | 2025-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.84 | 9,208 | $127,430.43 | 100,206 | 2025-07-01 | Filing | |
| $13.37 | 10,139 | $135,573.64 | 109,414 | 2025-06-18 | Filing | |
| $13.78 | 1,800 | $24,806.52 | 202,599 | 2025-05-28 | Filing | |
| $14.07 | 7,451 | $104,849.73 | 183,104 | 2025-05-19 | Filing | |
| $13.59 | 3,871 | $52,623.15 | 115,468 | 2025-05-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,360,875 | $177,684,084 | 0.12% | |
| 2. | 8,892,337 | $139,076,152 | 0% | |
| 3. | 8,785,284 | $137,401,842 | 6.28% | |
| 4. | 6,818,078 | $106,634,740 | 0% | |
| 5. | 4,474,203 | $69,976,535 | 0% |
News See All
10 Best Small-Cap Growth Stocks to Buy According to Analysts
On March 26, Gabelli Funds released its small-cap 2025 outlook, highlighting the valuation discounts backing the small caps and the tailwinds from the macroeconomic backdrop.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript
Operator: Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2024 Earnings Call Transcript February 25, 2025Arcutis Biotherapeutics, Inc. beats earnings expectations.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Small Cap Stocks with High Potential
As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest rate cuts and the consequent impacts on stock and bond performances, investors are...
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript
Operator: Good day and welcome to Arcutis Biotherapeutics' 2024 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
